WallStreetZenWallStreetZen

NASDAQ: CTXR
Citius Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CTXR

Based on 1 analyst offering 12 month price targets for Citius Pharmaceuticals Inc

Min Forecast
$4.00+625.95%
Avg Forecast
$4.00+625.95%
Max Forecast
$4.00+625.95%

Should I buy or sell CTXR stock?

Based on 1 analyst offering ratings for Citius Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTXR stock forecasts and price targets.

CTXR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-18

1 of 1

Forecast return on equity

Is CTXR forecast to generate an efficient return?

Company
-4.2%
Industry
30.63%
Market
174.61%
CTXR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTXR forecast to generate an efficient return on assets?

Company
-1.97%
Industry
20.43%
CTXR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTXR earnings per share forecast

What is CTXR's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.47
Avg 2 year Forecast
-$0.68
Avg 3 year Forecast
-$0.10

CTXR revenue forecast

What is CTXR's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$20.9M+194.6%
Avg 2 year Forecast
$51.7M+627.5%
Avg 3 year Forecast
$76.1M+971.31%
CTXR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTXR revenue growth forecast

How is CTXR forecast to perform vs Biotechnology companies and vs the US market?

Company
121.46%
Industry
29.39%
Market
12.3%
CTXR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTXR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTXR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CTXR$0.55$4.00+625.95%Buy
ATYR$6.18$140.00+2,165.37%Strong Buy
PLUR$1.23N/AN/A
ABOS$0.22$1.00+362.96%Buy
TCRX$0.21$1.00+376.19%Hold
View Top Biotech Stocks

Citius Pharmaceuticals Stock Forecast FAQ

Is Citius Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CTXR) stock is to Buy CTXR stock.

Out of 1 analyst, 0 (0%) are recommending CTXR as a Strong Buy, 1 (100%) are recommending CTXR as a Buy, 0 (0%) are recommending CTXR as a Hold, 0 (0%) are recommending CTXR as a Sell, and 0 (0%) are recommending CTXR as a Strong Sell.

If you're new to stock investing, here's how to buy Citius Pharmaceuticals stock.

What is CTXR's earnings growth forecast for 2027-2029?

(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.18%.

Citius Pharmaceuticals's earnings in 2026 is -$46,274,056.On average, 3 Wall Street analysts forecast CTXR's earnings for 2027 to be -$40,322,335, with the lowest CTXR earnings forecast at -$38,741,067, and the highest CTXR earnings forecast at -$41,508,286. On average, 3 Wall Street analysts forecast CTXR's earnings for 2028 to be -$18,761,086, with the lowest CTXR earnings forecast at -$18,025,357, and the highest CTXR earnings forecast at -$19,312,883.

In 2029, CTXR is forecast to generate -$2,800,162 in earnings, with the lowest earnings forecast at -$2,690,352 and the highest earnings forecast at -$2,882,520.

What is CTXR's revenue growth forecast for 2027-2029?

(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual revenue growth rate of 121.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.3%.

Citius Pharmaceuticals's revenue in 2026 is $7,105,197.On average, 3 Wall Street analysts forecast CTXR's revenue for 2027 to be $574,637,195, with the lowest CTXR revenue forecast at $552,126,088, and the highest CTXR revenue forecast at $591,547,978. On average, 3 Wall Street analysts forecast CTXR's revenue for 2028 to be $1,419,023,343, with the lowest CTXR revenue forecast at $1,363,349,531, and the highest CTXR revenue forecast at $1,460,751,250.

In 2029, CTXR is forecast to generate $2,089,662,176 in revenue, with the lowest revenue forecast at $2,007,688,802 and the highest revenue forecast at $2,151,101,027.

What is CTXR's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: CTXR) forecast ROA is -1.97%, which is lower than the forecast US Biotechnology industry average of 20.43%.

What is CTXR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CTXR price target, the average CTXR price target is $4.00, with the highest CTXR stock price forecast at $4.00 and the lowest CTXR stock price forecast at $4.00.

The Wall Street analyst predicted that Citius Pharmaceuticals's share price could reach $4.00 by May 18, 2027. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 625.95% from the current CTXR share price of $0.55.

What is CTXR's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: CTXR) Citius Pharmaceuticals's current Earnings Per Share (EPS) is -$1.78. On average, analysts forecast that CTXR's EPS will be -$1.47 for 2027, with the lowest EPS forecast at -$1.41, and the highest EPS forecast at -$1.51. On average, analysts forecast that CTXR's EPS will be -$0.68 for 2028, with the lowest EPS forecast at -$0.66, and the highest EPS forecast at -$0.70. In 2029, CTXR's EPS is forecast to hit -$0.10 (min: -$0.10, max: -$0.11).

What is CTXR's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: CTXR) forecast ROE is -4.2%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.